Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 475

1.

Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM).

Karimian-Jazi K, Münch P, Alexander A, Fischer M, Pfleiderer K, Piechutta M, Karreman MA, Solecki GM, Berghoff AS, Friedrich M, Deumelandt K, Kurz FT, Wick W, Heiland S, Bendszus M, Winkler F, Platten M, Breckwoldt MO.

Theranostics. 2020 Jan 1;10(4):1873-1883. doi: 10.7150/thno.38659. eCollection 2020.

2.

Not yet another negative trial - ReACTing on recent glioblastoma trials!

Wick W, Wagener RJ.

Clin Cancer Res. 2020 Feb 7. pii: clincanres.4032.2019. doi: 10.1158/1078-0432.CCR-19-4032. [Epub ahead of print]

PMID:
32034079
3.

Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.

Kessler T, Latzer P, Schmid D, Warnken U, Saffari A, Ziegler A, Kollmer J, Möhlenbruch M, Ulfert C, Herweh C, Wildemann B, Wick W, Weiler M.

J Neurochem. 2020 Jan 6:e14953. doi: 10.1111/jnc.14953. [Epub ahead of print]

PMID:
31903607
4.

Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis.

Brugnara G, Isensee F, Neuberger U, Bonekamp D, Petersen J, Diem R, Wildemann B, Heiland S, Wick W, Bendszus M, Maier-Hein K, Kickingereder P.

Eur Radiol. 2020 Jan 3. doi: 10.1007/s00330-019-06593-y. [Epub ahead of print]

PMID:
31900702
5.

Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14.

Deng MY, Sill M, Sturm D, Stichel D, Witt H, Ecker J, Wittmann A, Schittenhelm J, Ebinger M, Schuhmann MU, Figarella-Branger D, Aronica E, Staszewski O, Preusser M, Haberler C, Lauten M, Schüller U, Hartmann C, Snuderl M, Dunham C, Jabado N, Wesseling P, Deckert M, Keyvani K, Gottardo N, Giangaspero F, von Hoff K, Ellison DW, Pietsch T, Herold-Mende C, Milde T, Witt O, Kool M, Korshunov A, Wick W, von Deimling A, Pfister SM, Jones DTW, Sahm F.

Neuropathol Appl Neurobiol. 2019 Dec 23. doi: 10.1111/nan.12590. [Epub ahead of print]

PMID:
31867747
6.

Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.

Al-Ali R, Bauer K, Park JW, Al Abdulla R, Fermi V, von Deimling A, Herold-Mende C, Mallm JP, Herrmann C, Wick W, Turcan Ş.

Acta Neuropathol Commun. 2019 Dec 5;7(1):201. doi: 10.1186/s40478-019-0851-y.

7.

cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.

Berberich A, Schmitt LM, Pusch S, Hielscher T, Rübmann P, Hucke N, Latzer P, Heßling B, Lemke D, Kessler T, Platten M, Wick W.

J Neurooncol. 2020 Jan;146(1):9-23. doi: 10.1007/s11060-019-03348-z. Epub 2019 Nov 28.

PMID:
31776900
8.

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.

van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY, Lassman AB, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Cheng Y, Vicente S, Balbin OA, Zhang H, Wick W.

J Neurooncol. 2020 Jan;146(1):79-89. doi: 10.1007/s11060-019-03337-2. Epub 2019 Nov 27.

9.

Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.

Seystahl K, Hentschel B, Loew S, Gramatzki D, Felsberg J, Herrlinger U, Westphal M, Schackert G, Thon N, Tatagiba M, Pietsch T, Reifenberger G, Löffler M, Wick W, Weller M; German Glioma Network.

J Cancer Res Clin Oncol. 2019 Nov 21. doi: 10.1007/s00432-019-03086-9. [Epub ahead of print]

PMID:
31754832
10.

YAP1-fusions in pediatric NF2-wildtype meningioma.

Sievers P, Chiang J, Schrimpf D, Stichel D, Paramasivam N, Sill M, Gayden T, Casalini B, Reuss DE, Dalton J, Pajtler KW, Hänggi D, Herold-Mende C, Rushing E, Korshunov A, Mawrin C, Weller M, Schlesner M, Wick W, Jabado N, Jones DTW, Pfister SM, von Deimling A, Ellison DW, Sahm F.

Acta Neuropathol. 2020 Jan;139(1):215-218. doi: 10.1007/s00401-019-02095-9. Epub 2019 Nov 16. No abstract available.

PMID:
31734728
11.

Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation.

Sievers P, Schrimpf D, Stichel D, Reuss DE, Hasselblatt M, Hagel C, Staszewski O, Hench J, Frank S, Brandner S, Korshunov A, Wick W, Pfister SM, Reifenberger G, von Deimling A, Sahm F, Jones DTW.

Acta Neuropathol. 2020 Feb;139(2):403-406. doi: 10.1007/s00401-019-02097-7. Epub 2019 Nov 15. No abstract available.

PMID:
31729570
12.

Emerging intersections between neuroscience and glioma biology.

Jung E, Alfonso J, Osswald M, Monyer H, Wick W, Winkler F.

Nat Neurosci. 2019 Dec;22(12):1951-1960. doi: 10.1038/s41593-019-0540-y. Epub 2019 Nov 12. Review.

PMID:
31719671
13.

Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?

Coomans MB, Dirven L, Aaronson NK, Baumert BG, Van Den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB.

Neuro Oncol. 2019 Nov 4;21(11):1447-1457. doi: 10.1093/neuonc/noz118.

14.

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.

Wick W, Krendyukov A, Junge K, Höger T, Fricke H.

J Neurooncol. 2019 Dec;145(3):531-540. doi: 10.1007/s11060-019-03320-x. Epub 2019 Nov 2.

15.

Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities.

Reinhardt A, Stichel D, Schrimpf D, Koelsche C, Wefers AK, Ebrahimi A, Sievers P, Huang K, Casalini MB, Fernández-Klett F, Suwala A, Weller M, Gramatzki D, Felsberg J, Reifenberger G, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Buslei R, Deckert M, Mawrin C, Hewer E, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Korshunov A, Reuss DE, Sahm F, Jones DTW, Capper D, von Deimling A.

Acta Neuropathol Commun. 2019 Oct 28;7(1):163. doi: 10.1186/s40478-019-0801-8.

16.

Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology.

Sonner JK, Keil M, Falk-Paulsen M, Mishra N, Rehman A, Kramer M, Deumelandt K, Röwe J, Sanghvi K, Wolf L, von Landenberg A, Wolff H, Bharti R, Oezen I, Lanz TV, Wanke F, Tang Y, Brandao I, Mohapatra SR, Epping L, Grill A, Röth R, Niesler B, Meuth SG, Opitz CA, Okun JG, Reinhardt C, Kurschus FC, Wick W, Bode HB, Rosenstiel P, Platten M.

Nat Commun. 2019 Oct 25;10(1):4877. doi: 10.1038/s41467-019-12776-4.

17.

Association of General Anesthesia vs Procedural Sedation With Functional Outcome Among Patients With Acute Ischemic Stroke Undergoing Thrombectomy: A Systematic Review and Meta-analysis.

Schönenberger S, Hendén PL, Simonsen CZ, Uhlmann L, Klose C, Pfaff JAR, Yoo AJ, Sørensen LH, Ringleb PA, Wick W, Kieser M, Möhlenbruch MA, Rasmussen M, Rentzos A, Bösel J.

JAMA. 2019 Oct 1;322(13):1283-1293. doi: 10.1001/jama.2019.11455. Erratum in: JAMA. 2019 Dec 24;322(24):2445.

PMID:
31573636
18.

Glutamatergic synaptic input to glioma cells drives brain tumour progression.

Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, Körber C, Kardorff M, Ratliff M, Xie R, Horstmann H, Messer M, Paik SP, Knabbe J, Sahm F, Kurz FT, Acikgöz AA, Herrmannsdörfer F, Agarwal A, Bergles DE, Chalmers A, Miletic H, Turcan S, Mawrin C, Hänggi D, Liu HK, Wick W, Winkler F, Kuner T.

Nature. 2019 Sep;573(7775):532-538. doi: 10.1038/s41586-019-1564-x. Epub 2019 Sep 18.

PMID:
31534219
19.

EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Goldbrunner R, Weller M, Regis J, Lund-Johansen M, Stavrinou P, Reuss D, Evans DG, Lefranc F, Sallabanda K, Falini A, Axon P, Sterkers O, Fariselli L, Wick W, Tonn JC.

Neuro Oncol. 2020 Jan 11;22(1):31-45. doi: 10.1093/neuonc/noz153.

PMID:
31504802
20.

Automated brain extraction of multisequence MRI using artificial neural networks.

Isensee F, Schell M, Pflueger I, Brugnara G, Bonekamp D, Neuberger U, Wick A, Schlemmer HP, Heiland S, Wick W, Bendszus M, Maier-Hein KH, Kickingereder P.

Hum Brain Mapp. 2019 Dec 1;40(17):4952-4964. doi: 10.1002/hbm.24750. Epub 2019 Aug 12.

PMID:
31403237
21.

Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.

Furtner J, Genbrugge E, Gorlia T, Bendszus M, Nowosielski M, Golfinopoulos V, Weller M, van den Bent MJ, Wick W, Preusser M.

Neuro Oncol. 2019 Dec 17;21(12):1587-1594. doi: 10.1093/neuonc/noz131.

PMID:
31369680
22.

Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy.

Kollmer J, Hilgenfeld T, Ziegler A, Saffari A, Sam G, Hayes JM, Pietsch A, Jost M, Heiland S, Bendszus M, Wick W, Weiler M.

Neurology. 2019 Aug 13;93(7):e653-e664. doi: 10.1212/WNL.0000000000007945. Epub 2019 Jul 10.

PMID:
31292223
23.

Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions.

Stichel D, Schrimpf D, Casalini B, Meyer J, Wefers AK, Sievers P, Korshunov A, Koelsche C, Reuss DE, Reinhardt A, Ebrahimi A, Fernández-Klett F, Kessler T, Sturm D, Ecker J, Milde T, Herold-Mende C, Witt O, Pfister SM, Wick W, Jones DTW, von Deimling A, Sahm F.

Acta Neuropathol. 2019 Nov;138(5):827-835. doi: 10.1007/s00401-019-02039-3. Epub 2019 Jul 5.

PMID:
31278449
24.

Can Virtual Contrast Enhancement in Brain MRI Replace Gadolinium?: A Feasibility Study.

Kleesiek J, Morshuis JN, Isensee F, Deike-Hofmann K, Paech D, Kickingereder P, Köthe U, Rother C, Forsting M, Wick W, Bendszus M, Schlemmer HP, Radbruch A.

Invest Radiol. 2019 Oct;54(10):653-660. doi: 10.1097/RLI.0000000000000583.

PMID:
31261293
25.

Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1.

Sievers P, Appay R, Schrimpf D, Stichel D, Reuss DE, Wefers AK, Reinhardt A, Coras R, Ruf VC, Schmid S, de Stricker K, Boldt HB, Kristensen BW, Petersen JK, Ulhøi BP, Gardberg M, Aronica E, Hasselblatt M, Brück W, Bielle F, Mokhtari K, Lhermitte B, Wick W, Herold-Mende C, Hänggi D, Brandner S, Giangaspero F, Capper D, Rushing E, Wesseling P, Pfister SM, Figarella-Branger D, von Deimling A, Sahm F, Jones DTW.

Acta Neuropathol. 2019 Sep;138(3):497-504. doi: 10.1007/s00401-019-02038-4. Epub 2019 Jun 27.

PMID:
31250151
26.

The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.

Coomans M, Dirven L, K Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group and the EORTC Brain Tumor Group.

Eur J Cancer. 2019 Jul;116:190-198. doi: 10.1016/j.ejca.2019.05.012. Epub 2019 Jun 13.

PMID:
31203194
27.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

28.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
29.

Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting.

Smits M, Bendszus M, Collette S, Postma LA, Dhermain F, Hagenbeek RE, Clement PM, Liu Y, Wick W, van den Bent MJ, Heiland S.

Eur J Cancer. 2019 Jun;114:89-96. doi: 10.1016/j.ejca.2019.03.007. Epub 2019 May 9.

PMID:
31078973
30.

Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.

Nowosielski M, Gorlia T, Bromberg JEC, Sahm F, Harting I, Kickingereder P, Brandes AA, Taphoorn MJB, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Weller M, Fabbro M, Le Rhun E, Platten M, Golfinopoulos V, van den Bent MJ, Bendszus M, Wick W.

Neurology. 2019 Jun 11;92(24):e2754-e2763. doi: 10.1212/WNL.0000000000007643. Epub 2019 May 10.

PMID:
31076534
31.

Mutational patterns and regulatory networks in epigenetic subgroups of meningioma.

Paramasivam N, Hübschmann D, Toprak UH, Ishaque N, Neidert M, Schrimpf D, Stichel D, Reuss D, Sievers P, Reinhardt A, Wefers AK, Jones DTW, Gu Z, Werner J, Uhrig S, Wirsching HG, Schick M, Bewerunge-Hudler M, Beck K, Brehmer S, Urbschat S, Seiz-Rosenhagen M, Hänggi D, Herold-Mende C, Ketter R, Eils R, Ram Z, Pfister SM, Wick W, Weller M, Grossmann R, von Deimling A, Schlesner M, Sahm F.

Acta Neuropathol. 2019 Aug;138(2):295-308. doi: 10.1007/s00401-019-02008-w. Epub 2019 May 8.

PMID:
31069492
32.

DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.

Binder H, Willscher E, Loeffler-Wirth H, Hopp L, Jones DTW, Pfister SM, Kreuz M, Gramatzki D, Fortenbacher E, Hentschel B, Tatagiba M, Herrlinger U, Vatter H, Matschke J, Westphal M, Krex D, Schackert G, Tonn JC, Schlegel U, Steiger HJ, Wick W, Weber RG, Weller M, Loeffler M.

Acta Neuropathol Commun. 2019 Apr 25;7(1):59. doi: 10.1186/s40478-019-0704-8.

33.

Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.

Kickingereder P, Isensee F, Tursunova I, Petersen J, Neuberger U, Bonekamp D, Brugnara G, Schell M, Kessler T, Foltyn M, Harting I, Sahm F, Prager M, Nowosielski M, Wick A, Nolden M, Radbruch A, Debus J, Schlemmer HP, Heiland S, Platten M, von Deimling A, van den Bent MJ, Gorlia T, Wick W, Bendszus M, Maier-Hein KH.

Lancet Oncol. 2019 May;20(5):728-740. doi: 10.1016/S1470-2045(19)30098-1. Epub 2019 Apr 2.

PMID:
30952559
34.

Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma.

Solecki G, Osswald M, Weber D, Glock M, Ratliff M, Müller HJ, Krieter O, Kienast Y, Wick W, Winkler F.

Cancers (Basel). 2019 Mar 6;11(3). pii: E314. doi: 10.3390/cancers11030314.

35.

Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.

Paech D, Dreher C, Regnery S, Meissner JE, Goerke S, Windschuh J, Oberhollenzer J, Schultheiss M, Deike-Hofmann K, Bickelhaupt S, Radbruch A, Zaiss M, Unterberg A, Wick W, Bendszus M, Bachert P, Ladd ME, Schlemmer HP.

Eur Radiol. 2019 Sep;29(9):4957-4967. doi: 10.1007/s00330-019-06066-2. Epub 2019 Feb 26.

PMID:
30809720
36.

Susceptibility-weighted imaging in malignant melanoma brain metastasis.

Schwarz D, Niederle T, Münch P, Hielscher T, Hassel JC, Schlemmer HP, Platten M, Winkler F, Wick W, Heiland S, Delorme S, Bendszus M, Bäumer P, Breckwoldt MO.

J Magn Reson Imaging. 2019 Oct;50(4):1251-1259. doi: 10.1002/jmri.26692. Epub 2019 Feb 21.

PMID:
30793419
37.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
38.

Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA.

Hou Y, Pinheiro J, Sahm F, Reuss DE, Schrimpf D, Stichel D, Casalini B, Koelsche C, Sievers P, Wefers AK, Reinhardt A, Ebrahimi A, Fernández-Klett F, Pusch S, Meier J, Schweizer L, Paulus W, Prinz M, Hartmann C, Plate KH, Reifenberger G, Pietsch T, Varlet P, Pagès M, Schüller U, Scheie D, de Stricker K, Frank S, Hench J, Pollo B, Brandner S, Unterberg A, Pfister SM, Jones DTW, Korshunov A, Wick W, Capper D, Blümcke I, von Deimling A, Bertero L.

Acta Neuropathol. 2019 May;137(5):837-846. doi: 10.1007/s00401-019-01969-2. Epub 2019 Feb 13.

PMID:
30759284
39.

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.

Schiff D, Van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY.

Neuro Oncol. 2019 Jul 11;21(7):837-853. doi: 10.1093/neuonc/noz033.

PMID:
30753579
40.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
41.

Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease.

Breckwoldt MO, Bode J, Sahm F, Krüwel T, Solecki G, Hahn A, Wirthschaft P, Berghoff AS, Haas M, Venkataramani V, von Deimling A, Wick W, Herold-Mende C, Heiland S, Platten M, Bendszus M, Kurz FT, Winkler F, Tews B.

Front Neurosci. 2019 Jan 10;12:1004. doi: 10.3389/fnins.2018.01004. eCollection 2018.

42.

Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche.

Chiblak S, Tang Z, Lemke D, Knoll M, Dokic I, Warta R, Moustafa M, Mier W, Brons S, Rapp C, Muschal S, Seidel P, Bendszus M, Adeberg S, Wiestler OD, Haberkorn U, Debus J, Herold-Mende C, Wick W, Abdollahi A.

JCI Insight. 2019 Jan 24;4(2). pii: 123837. doi: 10.1172/jci.insight.123837. [Epub ahead of print]

43.

The KEEP SIMPLEST Study: Improving In-House Delays and Periinterventional Management in Stroke Thrombectomy-A Matched Pair Analysis.

Schönenberger S, Weber D, Ungerer MN, Pfaff J, Schieber S, Uhlmann L, Heidenreich P, Bendszus M, Kieser M, Wick W, Möhlenbruch MA, Ringleb PA, Bösel J.

Neurocrit Care. 2019 Aug;31(1):46-55. doi: 10.1007/s12028-018-00667-3.

PMID:
30659468
44.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
45.

German Cancer Consortium (DKTK) - A national consortium for translational cancer research.

Joos S, Nettelbeck DM, Reil-Held A, Engelmann K, Moosmann A, Eggert A, Hiddemann W, Krause M, Peters C, Schuler M, Schulze-Osthoff K, Serve H, Wick W, Puchta J, Baumann M.

Mol Oncol. 2019 Mar;13(3):535-542. doi: 10.1002/1878-0261.12430. Epub 2019 Jan 9. Review.

46.

Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.

Eisemann T, Costa B, Harter PN, Wick W, Mittelbronn M, Angel P, Peterziel H.

Neuro Oncol. 2019 Feb 19;21(3):326-336. doi: 10.1093/neuonc/noy184.

PMID:
30418623
47.

Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p.

Sievers P, Stichel D, Hielscher T, Schrimpf D, Reinhardt A, Wefers AK, Reuss D, Jones DTW, Bewerunge-Hudler M, Hartmann C, Baumgarten P, Wirsching HG, Winther-Kristensen B, Brokinkel B, Ketter R, Idoate Gastearena MA, Lamszus K, Seiz-Rosenhagen M, Mawrin C, Harter PN, Felsberg J, Hänggi D, Herold-Mende C, Berghoff AS, Weller M, Pfister SM, Wick W, Reifenberger G, Preusser M, von Deimling A, Sahm F.

Acta Neuropathol. 2018 Dec;136(6):975-978. doi: 10.1007/s00401-018-1924-x. Epub 2018 Oct 31. No abstract available.

PMID:
30382370
48.

Integrated molecular characterization of IDH-mutant glioblastomas.

Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova M, Sharma T, Schrimpf D, Stichel D, Capper D, Reuss DE, Sturm D, Absalyamova O, Golanov A, Lambo S, Bewerunge-Hudler M, Lichter P, Herold-Mende C, Wick W, Pfister SM, Kool M, Jones DTW, von Deimling A, Sahm F.

Neuropathol Appl Neurobiol. 2019 Feb;45(2):108-118. doi: 10.1111/nan.12523. Epub 2018 Nov 15.

PMID:
30326163
49.

Steroid-Responsive Relapsing-Remitting Neutrophilic Encephalitis: A Case Report.

Ungerer MN, Diem R, Wrede A, Huang K, Hähnel S, Wick W, Winkler F.

J Neuropathol Exp Neurol. 2018 Nov 1;77(11):993-996. doi: 10.1093/jnen/nly088.

PMID:
30299484
50.

N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M.

Neuro Oncol. 2019 Jan 1;21(1):95-105. doi: 10.1093/neuonc/noy161.

Supplemental Content

Support Center